Literature DB >> 10584991

The "point of no return" and the rate of progression in the natural history of IgA nephritis.

U Schöll1, U Wastl, T Risler, N Braun, B Grabensee, P Heering, P Schollmeyer, I Zäuner, G Stein, R Fünfstück, F Keller.   

Abstract

BACKGROUND: Based on the observation of 7 patients with chronic IgA nephritis and on a course to end-stage renal failure after several years, D'Amico et al. [1993] reported on a "point of no return" at 2.5 to 3 mg/dl serum creatinine. After exceeding this limit all 7 patients exhibited an irreversible progressive renal failure. PATIENTS AND METHODS: Therefore, 115 patients with IgA nephritis from the "German Glomerulonephritis Therapy Study" were examined in order to look for the existence of such a "point of no return".
RESULTS: Three different courses could be distinguished: a stable chronic course with constantly normal or only minor elevated serum creatinine lasting for years (91 patients), a progressive course with continuously increasing serum creatinine (22 patients), and a rare (only 2 patients) early acute course with a short-term increase of serum creatinine followed by a rapid return to the normal range. After exceeding 3 mg/dl serum creatinine no remissions were observed in the progressive cases. Sixteen patients showed a rapid, continuously progressive course until end-stage renal failure with exactly the same progression as the 7 patients of D'Amico et al. Six patients of the 22 progressors were not observed long enough. The serum creatinine level doubled on average from 3 to 6 mg/dl within 10 months.
CONCLUSION: Our study confirmed the existence of a "point of no return" at 3 mg/dl (265 micromol/l) during the natural course of chronic IgA nephritis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10584991

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  9 in total

Review 1.  Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy?

Authors:  F M Rasche; F Keller; W G Rasche; S Schiekofer; A Boldt; U Sack; J Fahnert
Journal:  Clin Exp Immunol       Date:  2016-09-08       Impact factor: 4.330

2.  Sequential therapy with cyclophosphamide and mycophenolic acid in patients with progressive immunoglobulin A nephropathy: a long-term follow-up.

Authors:  F M Rasche; F Keller; W G Rasche; S Schiekofer; T Kahn; J Fahnert
Journal:  Clin Exp Immunol       Date:  2015-11-26       Impact factor: 4.330

3.  Treatment for IgA nephropathy with stage 3 or 4 chronic kidney disease: low-dose corticosteroids combined with oral cyclophosphamide.

Authors:  Feng Ma; Xiaoxia Yang; Meilan Zhou; Ming Bai; Lijuan Zhao; Li Li; Ruijuan Dong; Chunmei Liu; Rong Li; Shiren Sun
Journal:  J Nephrol       Date:  2020-05-23       Impact factor: 3.902

Review 4.  Treatment of IgA nephropathy and Henoch-Schönlein nephritis.

Authors:  Jürgen Floege; John Feehally
Journal:  Nat Rev Nephrol       Date:  2013-04-02       Impact factor: 28.314

Review 5.  Treatment of IgA nephropathy with renal insufficiency.

Authors:  Claudio Pozzi; Cristina Sarcina; Francesca Ferrario
Journal:  J Nephrol       Date:  2016-01-07       Impact factor: 3.902

6.  Histologically advanced IgA nephropathy treated successfully with prednisolone and cyclophosphamide.

Authors:  Koji Mitsuiki; Atsumi Harada; Takafumi Okura; Jitsuo Higaki
Journal:  Clin Exp Nephrol       Date:  2007-12-21       Impact factor: 2.801

Review 7.  Omega-3 fatty acid supplementation as an adjunctive therapy in the treatment of chronic kidney disease: a meta-analysis.

Authors:  Jing Hu; Zuoliang Liu; Hao Zhang
Journal:  Clinics (Sao Paulo)       Date:  2017-01-01       Impact factor: 2.365

8.  IgA nephropathy in Greece: data from the registry of the Hellenic Society of Nephrology.

Authors:  Maria Stangou; Marios Papasotiriou; Dimitrios Xydakis; Theodora Oikonomaki; Smaragdi Marinaki; Synodi Zerbala; Constantinos Stylianou; Pantelitsa Kalliakmani; Aimilios Andrikos; Antonia Papadaki; Olga Balafa; Spyridon Golfinopoulos; Georgios Visvardis; Georgios Moustakas; Evangelos Papachristou; Theodora Kouloukourgiotou; Eleni Kapsia; Angeliki Panagiotou; Constantinos Koulousios; Christos Kavlakoudis; Maria Georgopoulou; Stylianos Panagoutsos; Demetrios V Vlahakos; Theophanis Apostolou; Ioannis Stefanidis; Kostas Siamopoulos; Ioannis Tzanakis; Apostolos Papadogiannakis; Eugene Daphnis; Christos Iatrou; John N Boletis; Aikaterini Papagianni; Dimitrios S Goumenos
Journal:  Clin Kidney J       Date:  2017-07-31

9.  Corticosteroids in patients with IgA nephropathy and severe chronic renal damage.

Authors:  Claudio Pozzi; Francesca Ferrario; Bianca Visciano; Lucia Del Vecchio
Journal:  Case Rep Nephrol       Date:  2012-10-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.